Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Open-label Trial of Intrathecal Rituximab for Progressive Multiple Sclerosis Patients With Magnetic Resonance Imaging Evidence of Leptomeningeal Enhancement

NCT02253264 is registered in ClinicalTrials.gov with Johns Hopkins University as lead sponsor.

NCT NCT02253264
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02253264 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Open-label Trial of Intrathecal Rituximab for Progressive Multiple Sclerosis Patients With Magnetic Resonance Imaging Evidence of Leptomeningeal Enhancement
Lead sponsor
Johns Hopkins University
Phase
Phase 1
Overall status
Completed
Start date
November 30, 2014
Completion date
August 31, 2017
Enrollment
8 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

primary progressive multiple sclerosis, secondary progressive multiple sclerosis